Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.79 |
| ▸ | ALPL | P05186 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Higenamine SCHEMBL5898913 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (+)-Higenamine SCHEMBL30464469 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL29365055 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL30105922 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL636788 | 1.00 | DRD2 (1.00) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL5898916 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (-)-Higenamine SCHEMBL29374757 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| (+)-Higenamine SCHEMBL5898932 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL28478764 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 | |
| Higenamine SCHEMBL29623874 | 0.99 | DRD2 (0.97) | DRD2DRD4KDM1ATBXA2RADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | claimed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | claimed |
| CN-1630640-A | Novel enantiomer of tetra hydrogen isoquinoline derivative and officinal salt, preparation and pharmaceutical composition thereof | HOI-SU YOON CHOI (KR) | 2005-06-22 | — | — | CN | claimed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | claimed |
| WO-2003095426-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2003-11-20 | — | — | WO | claimed |
| US-10738335-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10662453-B2 | Compositions and methods for making (S)-norcoclaurine and (S)-norlaudanosoline, and synthesis intermediates thereof | Willow Biosciences Inc. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20190144900-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2019-05-16 | — | — | US | disclosed |
| CN-103626703-B | The preparation method of chirality demethyl coclaurine and derivative thereof | ZHUHAI RUNDU PHARMACEUTICAL CO., LTD. (CN) | 2015-11-11 | — | — | CN | disclosed |
| CN-103626703-A | Preparation method of chiral higenamine and derivatives of chiral higenamine | ZHUHAI RUNDU PHARMACEUTICAL CO LTD | 2014-03-12 | — | — | CN | disclosed |
| CN-100348583-C | Novel enantiomer of tetra hydrogen isoquinoline derivative and officinal salt, preparation and pharmaceutical composition thereof | YOON CHOI HOI SU (KR) | 2007-11-14 | — | — | CN | disclosed |
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | disclosed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | disclosed |
| CN-1630640-A | Novel enantiomer of tetra hydrogen isoquinoline derivative and officinal salt, preparation and pharmaceutical composition thereof | HOI-SU YOON CHOI (KR) | 2005-06-22 | — | — | CN | disclosed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003095426-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | TBXA2R, NOS2, TBXAS1 | DRD2 641/4885DRD4 1187/4885KDM1A 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.